AIM IMMUNOTECH (Germany) Investor Sentiment

HXB2 Stock  EUR 0.35  0.05  12.50%   
Roughly 67% of AIM IMMUNOTECH's investor base is looking to short. The analysis of current outlook of investing in AIM IMMUNOTECH INC suggests that many traders are alarmed regarding AIM IMMUNOTECH's prospects. AIM IMMUNOTECH's investor sentiment overview provides quick insight into current market opportunities from investing in AIM IMMUNOTECH INC. The current market sentiment, together with AIM IMMUNOTECH's historical and current headlines, can help investors time the market. In addition, many technical investors use AIM IMMUNOTECH INC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
AIM IMMUNOTECH stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of AIM daily returns and investor perception about the current price of AIM IMMUNOTECH INC as well as its diversification or hedging effects on your existing portfolios.
  
over two weeks ago at news.google.com         
AIM Stock Earnings AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023 - MSN
Google News at Macroaxis
over three weeks ago at news.google.com         
Navigating the Future Aim Immunotechs Challenge Against Rapid Tech Evolution in Pharma - TipRanks.co...
Google News at Macroaxis
over three weeks ago at news.google.com         
Reviewing AIM ImmunoTech and Finch Therapeutics Group - Defense World
Google News at Macroaxis
over three weeks ago at news.google.com         
AIM ImmunoTech to Present at the MedInvest Biotech Pharma Investor Conference - Yahoo Finance
Google News at Macroaxis
over three weeks ago at news.google.com         
Insider Buying AIM ImmunoTech Inc. Director Buys 38462 Shares of Stock - Defense World
Google News at Macroaxis
over a month ago at news.google.com         
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Yahoo Finance
Google News at Macroaxis
over a month ago at news.google.com         
Insider Buying AIM ImmunoTech Inc. CEO Buys 75758 Shares of Stock - Defense World
Google News at Macroaxis
over a month ago at news.google.com         
Aim ImmunoTech COO purchases 12,500 in company stock By Investing.com - Investing.com
Google News at Macroaxis
over a month ago at news.google.com         
AIM ImmunoTech Announces Launch of CEO Corner Platform - Marketscreener.com
Google News at Macroaxis
over a month ago at news.google.com         
AIM ImmunoTech Shares Down 2.2 percent - Defense World
Google News at Macroaxis
over a month ago at news.google.com         
Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value Senior ....
Google News at Macroaxis
over two months ago at news.google.com         
Promising Results from Phase 2 Study Ampligen Shows Potential as Treatment for PostCOVID Conditions ...
Google News at Macroaxis
over three months ago at news.google.com         
Delaware Court of Chancery Provides Roadmap for Evaluating Advance Notice Bylaws - Dentons
Google News at Macroaxis
over three months ago at news.google.com         
AIM ImmunoTech Provides Update Regarding Annual Meeting ... - Marketscreener.com
Google News at Macroaxis
over three months ago at news.google.com         
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 ... - Marketscreener.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about AIM IMMUNOTECH that are available to investors today. That information is available publicly through AIM media outlets and privately through word of mouth or via AIM internal channels. However, regardless of the origin, that massive amount of AIM data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AIM IMMUNOTECH news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AIM IMMUNOTECH relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AIM IMMUNOTECH's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AIM IMMUNOTECH alpha.

AIM IMMUNOTECH Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
Check out AIM IMMUNOTECH Hype Analysis, AIM IMMUNOTECH Correlation and AIM IMMUNOTECH Performance.
For more detail on how to invest in AIM Stock please use our How to Invest in AIM IMMUNOTECH guide.
Note that the AIM IMMUNOTECH INC information on this page should be used as a complementary analysis to other AIM IMMUNOTECH's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for AIM Stock analysis

When running AIM IMMUNOTECH's price analysis, check to measure AIM IMMUNOTECH's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM IMMUNOTECH is operating at the current time. Most of AIM IMMUNOTECH's value examination focuses on studying past and present price action to predict the probability of AIM IMMUNOTECH's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM IMMUNOTECH's price. Additionally, you may evaluate how the addition of AIM IMMUNOTECH to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamental Analysis
View fundamental data based on most recent published financial statements
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Please note, there is a significant difference between AIM IMMUNOTECH's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM IMMUNOTECH is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM IMMUNOTECH's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.